Neoleukin Therapeutics Inc. announced the appointment of Rohan Palekar, Chief Executive Officer of 89bio, Inc, to Neoleukin's Board of Directors, and the departure of Lewis Rusty Williams, MD, PhD, from the board. Mr. Palekar has served as the CEO of 89bio since June 2018.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.23 USD | -0.98% | +15.95% | +92.11% |
06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+92.11% | 483M | |
+48.64% | 56.65B | |
-6.44% | 39.44B | |
+38.03% | 39.03B | |
+14.28% | 26.75B | |
-11.17% | 26.86B | |
-21.40% | 19.03B | |
+25.64% | 12.26B | |
+0.96% | 12.28B | |
+27.04% | 12.04B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neoleukin Therapeutics Inc. Announces Executive Changes